(LFST) Lifestance Health - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 2.822m USD | Total Return: 24.9% in 12m
Avg Turnover: 29.6M
Qual. Beats: 0
Rev. Trend: 99.6%
Qual. Beats: 1
Warnings
P/E ratio 123.2
Altman Z'' -1.95 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
LifeStance Health Group, Inc. (LFST) is a Scottsdale-based provider of outpatient mental health services across the United States. The company utilizes a multidisciplinary approach to treat a broad demographic, ranging from pediatric to geriatric patients, through both in-person clinics and a proprietary digital platform. Its clinical scope encompasses psychiatric evaluations, psychological testing, and various therapy modalities for conditions such as anxiety, depression, and PTSD.
Operating in the fragmented behavioral health sector, LifeStance follows a hybrid business model that integrates traditional brick-and-mortar centers with telehealth capabilities to increase patient access. This sector is characterized by high demand and a structural shortage of licensed clinicians, making provider recruitment and retention critical components of the operational strategy.
For a more comprehensive look at the companys valuation and long-term growth prospects, consider exploring the detailed financial metrics available on ValueRay.
- Clinician retention rates impact therapist capacity and high-margin service delivery volume
- Commercial payer reimbursement rate negotiations determine consolidated net revenue margins
- Operational shift toward organic clinician recruitment reduces inorganic acquisition capital expenditure
- Expansion of digital telehealth platform scales patient volume with lower facility overhead
- Federal mental health parity regulations influence insurance coverage and patient access levels
| Net Income: 23.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.47 > 1.0 |
| NWC/Revenue: 7.77% < 20% (prev 7.58%; Δ 0.20% < -1%) |
| CFO/TA 0.08 > 3% & CFO 182.4m > Net Income 23.2m |
| Net Debt (311.2m) to EBITDA (99.1m): 3.14 < 3 |
| Current Ratio: 1.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (395.1m) vs 12m ago 1.13% < -2% |
| Gross Margin: 29.87% > 18% (prev 0.33%; Δ 2.95k% > 0.5%) |
| Asset Turnover: 70.33% > 50% (prev 60.98%; Δ 9.35% > 0%) |
| Interest Coverage Ratio: 6.59 > 6 (EBITDA TTM 99.1m / Interest Expense TTM 6.80m) |
| A: 0.05 (Total Current Assets 355.9m - Total Current Liabilities 239.7m) / Total Assets 2.15b |
| B: -0.37 (Retained Earnings -794.4m / Total Assets 2.15b) |
| C: 0.02 (EBIT TTM 44.8m / Avg Total Assets 2.13b) |
| D: -1.18 (Book Value of Equity -790.5m / Total Liabilities 668.5m) |
| Altman-Z'' = -1.95 = D |
| DSRI: 0.75 (Receivables 122.9m/140.4m, Revenue 1.49b/1.28b) |
| GMI: 1.09 (GM 29.87% / 32.53%) |
| AQI: 0.97 (AQ_t 0.69 / AQ_t-1 0.71) |
| SGI: 1.16 (Revenue 1.49b / 1.28b) |
| TATA: -0.07 (NI 23.2m - CFO 182.4m) / TA 2.15b) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 7.57 with a total of 2,264,722 shares traded.
Over the past week, the price has changed by -2.95%,
over one month by +4.13%,
over three months by +8.76% and
over the past year by +24.92%.
Lifestance Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy LFST.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.7 | 41.6% |
P/E Trailing = 123.1667
P/E Forward = 49.2611
P/S = 1.8877
P/B = 1.9099
Revenue TTM = 1.49b USD
EBIT TTM = 44.8m USD
EBITDA TTM = 99.1m USD
Long Term Debt = 262.5m USD (from longTermDebt, last quarter)
Short Term Debt = 47.4m USD (from shortTermDebt, last quarter)
Debt = 506.0m USD (corrected: LT Debt 262.5m + ST Debt 47.4m) + Leases 196.2m
Net Debt = 311.2m USD (calculated: Debt 506.0m - CCE 194.8m)
Enterprise Value = 3.13b USD (2.82b + Debt 506.0m - CCE 194.8m)
Interest Coverage Ratio = 6.59 (Ebit TTM 44.8m / Interest Expense TTM 6.80m)
EV/FCF = 17.53x (Enterprise Value 3.13b / FCF TTM 178.8m)
FCF Yield = 5.71% (FCF TTM 178.8m / Enterprise Value 3.13b)
FCF Margin = 11.96% (FCF TTM 178.8m / Revenue TTM 1.49b)
Net Margin = 1.55% (Net Income TTM 23.2m / Revenue TTM 1.49b)
Gross Margin = 29.87% ((Revenue TTM 1.49b - Cost of Revenue TTM 1.05b) / Revenue TTM)
Gross Margin QoQ = 30.39% (prev 29.53%)
Tobins Q-Ratio = 1.46 (Enterprise Value 3.13b / Total Assets 2.15b)
Interest Expense / Debt = 1.34% (Interest Expense 6.80m / Debt 506.0m)
Taxrate = 27.92% (5.52m / 19.8m)
NOPAT = 32.3m (EBIT 44.8m * (1 - 27.92%))
Current Ratio = 1.48 (Total Current Assets 355.9m / Total Current Liabilities 239.7m)
Debt / Equity = 0.34 (Debt 506.0m / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = 3.14 (Net Debt 311.2m / EBITDA 99.1m)
Debt / FCF = 1.74 (Net Debt 311.2m / FCF TTM 178.8m)
Total Stockholder Equity = 1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.09% (Net Income 23.2m / Total Assets 2.15b)
RoE = 1.01% (Net Income TTM 23.2m / Total Stockholder Equity 2.29b)
RoCE = 1.76% (EBIT 44.8m / Capital Employed (Equity 2.29b + L.T.Debt 262.5m))
RoIC = 1.66% (NOPAT 32.3m / Invested Capital 1.94b)
WACC = 7.52% (E(2.82b)/V(3.33b) * Re(8.69%) + D(506.0m)/V(3.33b) * Rd(1.34%) * (1-Tc(0.28)))
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 1.90%
[DCF] Terminal Value 77.97% ; FCFF base≈148.2m ; Y1≈169.9m ; Y5≈250.0m
[DCF] Fair Price = 9.04 (EV 3.76b - Net Debt 311.2m = Equity 3.45b / Shares 381.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.51 | # QB: 0
Revenue Correlation: 99.64 | Revenue CAGR: 16.74% | SUE: 3.69 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.08 | Chg30d=+25.04% | Revisions=+50% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.07 | Chg30d=-4.58% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=0.32 | Chg30d=+4.64% | Revisions=+14% | GrowthEPS=+72.9% | GrowthRev=+16.6%
EPS next Year (2027-12-31): EPS=0.40 | Chg30d=+3.40% | Revisions=+25% | GrowthEPS=+25.3% | GrowthRev=+14.1%
[Analyst] Revisions Ratio: +50%